Insider Selling: ADMA Biologics, Inc. (NASDAQ:ADMA) CFO Sells 15,000 Shares of Stock

ADMA Biologics, Inc. (NASDAQ:ADMA) CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

ADMA Biologics Stock Down 0.6 %

Shares of ADMA Biologics stock traded down $0.12 during midday trading on Friday, reaching $21.18. 2,104,407 shares of the company’s stock traded hands, compared to its average volume of 3,637,081. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 52 week low of $3.60 and a 52 week high of $23.64. The company’s 50 day simple moving average is $18.80 and its 200 day simple moving average is $14.73. The company has a market cap of $5.01 billion, a price-to-earnings ratio of 76.07 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same quarter in the prior year, the company posted $0.01 EPS. Equities analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. Raymond James boosted their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th. Finally, HC Wainwright raised their price target on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th.

Hedge Funds Weigh In On ADMA Biologics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. USA Financial Formulas grew its position in shares of ADMA Biologics by 8.6% in the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 539 shares during the last quarter. Vontobel Holding Ltd. boosted its stake in ADMA Biologics by 7.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock valued at $273,000 after purchasing an additional 888 shares during the period. Hollencrest Capital Management acquired a new stake in ADMA Biologics in the 3rd quarter valued at approximately $30,000. Mirae Asset Global Investments Co. Ltd. increased its position in ADMA Biologics by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock worth $163,000 after buying an additional 1,509 shares during the period. Finally, Larson Financial Group LLC bought a new position in ADMA Biologics during the third quarter worth $31,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.